Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03572738 · ClinicalTrials.gov registry record
Hidradenitis Suppurativa Mail Survey
A clinical trial of Hidradenitis Suppurativa, sponsored by Wake Forest University Health Sciences.
- Completed
- Registry status
- 67
- Enrollment target
- 1
- Study location
NCT03572738 is a study of Hidradenitis Suppurativa that has completed, run by Wake Forest University Health Sciences. The registered enrollment target is 67 participants, below the 597-participant average among 52 other Hidradenitis Suppurativa trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03572738, a study of Hidradenitis Suppurativa, has completed, sponsored by Wake Forest University Health Sciences.
- COMPLETED
- Registry status
- 67 participants
- Enrollment target
- 1
- Study location
Study Summary
Hidradenitis Suppurativa (HS), also known as "acne inversa," is a chronic dermatologic disease affecting apocrine gland-bearing areas and presenting with symptoms ranging from pustules and inflammatory nodules to draining sinuses, abscesses, and fistulae. The pain and odorous lesions associated with HS contribute to its heightened impact on quality of life in comparison to other diseases; it has been described as "one of the most distressing conditions observed in dermatology." Though it is clear that HS has a significant impact on quality of life, how this manifests remains poorly characterized. The aim of this study is to characterize the quality of life impact of HS and to validate a tool for patients to self-assess the severity of their condition.
Conditions Studied
Study Locations (1)
North Carolina
- Wake Forest Baptist Medical Center - Winston-Salem
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 67 participants |
| Start Date | 2018-05-14 |
| Est. Completion | 2025-01-22 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03572738
The ClinicalTrials.gov registry entry for NCT03572738 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 67 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 597-participant average among 52 other Hidradenitis Suppurativa trials with a reported enrollment target (89% lower). The listed sponsor is Wake Forest University Health Sciences, which has 1,140 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hidradenitis Suppurativa appearing as the primary indexed condition, and to 0 interventions.
NCT03572738 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.
Frequently Asked Questions
What is clinical trial NCT03572738 about?
NCT03572738 is a clinical study titled "Hidradenitis Suppurativa Mail Survey". Hidradenitis Suppurativa (HS), also known as "acne inversa," is a chronic dermatologic disease affecting apocrine gland-bearing areas and presenting with symptoms ranging from pustules and inflammatory nodules to draining sinuses, abscesses, and fistulae. The pain and odorous lesions associated with...
What is the current status of trial NCT03572738?
This trial is currently completed. The enrollment target is 67 participants. The study started on 2018-05-14. Estimated completion is 2025-01-22.
What conditions does trial NCT03572738 study?
This clinical trial studies the following conditions: Hidradenitis Suppurativa.
Who is sponsoring clinical trial NCT03572738?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03572738 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hidradenitis Suppurativa
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Aviclear for Hidradenitis Suppurativa (HS)
RECRUITING · NA
-
Topical Ruxolitinib 1.5% for Hidradenitis Suppurativa Treatment
RECRUITING · Phase 2
-
A Study to Assess the Concentration of Bimekizumab in Mature Breast Milk From Mothers Receiving Treatment With Bimzelx® (Bimekizumab)
RECRUITING · Phase 1
-
An Open-label, Single-arm Study to Evaluate Pharmacokinetics and Safety of Subcutaneous Sonelokimab in Adolescents With Moderate to Severe Hidradenitis Suppurativa (VELA-TEEN)
RECRUITING · Phase 3
-
A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa
RECRUITING · Phase 3
-
Study to Evaluate the Maximal Use of Ruxolitinib Cream in Adult and Adolescent Participants With Hidradenitis Suppurativa
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.